Seeking Alpha

Regeneron (REGN -8.5%) dives after privately-owned Opthotech reports positive Phase 2b results...

Regeneron (REGN -8.5%) dives after privately-owned Opthotech reports positive Phase 2b results for its Fovista drug. Fovista, working in tandem with Roche's (RHHBY.PK) Lucentis, treats a form of macular degeneration, and stands to compete with Regeneron's Eylea. Lucentis. Jefferies is defending Regeneron, arguing Fovista could just as well work in tandem with Eylea.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)